Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life –– a double‐blind, placebo‐controlled study

@article{Guglielmetti2011RandomisedCT,
  title={Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life –– a double‐blind, placebo‐controlled study},
  author={Simone Guglielmetti and Diego Mora and Michael Gschwender and K Popp},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2011},
  volume={33}
}
Aliment Pharmacol Ther 2011; 33: 1123–1132 

Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence‐based international consensus

In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems.

Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome

TLDR
It is necessary to select patients suitable for vaginal or laparoscopic mesh placement for IBS preoperatively on the basis of prior history and once they provide informed consent for surgery.

Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria

TLDR
The withdrawal, due to adverse events, of a number of pharmacological agents that were approved for the treatment of IBS has left a therapeutic vacuum for patients suffering from the disorder.

Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide

TLDR
Evidence suggests that the gut microbiota play an important role in gastrointestinal problems and the importance of knowing the phytochemical components of the gut flora is important for the protection of against disease.

Microbiota profile and efficacy of probiotic supplementation on laxation in adults affected by Prader‐Willi Syndrome: A randomized, double‐blind, crossover trial

TLDR
Probiotics may provide a benefit for adults with Prader‐Willi syndrome (PWS) experiencing constipation if Bifidobacterium animalis ssp.

Meta‐analysis: antibiotic therapy for small intestinal bacterial overgrowth

Small intestinal bacterial overgrowth (SIBO) is an under‐recognised diagnosis with important clinical implications when untreated. However, the optimal treatment regimen remains unclear.

Systematic review with meta‐analysis: the efficacy of probiotics in inflammatory bowel disease

Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis.

Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome: authors’ reply

TLDR
1. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – a double-blind, placebo-controlled study.
...

References

SHOWING 1-10 OF 36 REFERENCES

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study

TLDR
This data indicates that using probiotics to treat irritable bowel syndrome with a low dose increases the likelihood that the drug will be effective in the long term.

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

Abstract  Aim:  To evaluate the effects of a combination probiotic on symptoms and colonic transit in patients with irritable bowel syndrome (IBS) and significant bloating.

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6‐month intervention

TLDR
The presence of probiotics inIrritable bowel syndrome is a gastrointestinal disorder of unknown aetiology and the effect of Probiotics in this syndrome remains unclear.

Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

TLDR
This data indicates that modulation of gut microflora‐mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome and may have an important role in selecting patients suitable for IBS.

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea‐predominant irritable bowel syndrome

TLDR
The intestinal permeability is increased in patients with diarrhoea‐predominant irritable bowel syndrome (D‐IBS) and this increased permeability increases the likelihood that the patient will have diarrhea and/or constipation.

Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial

Background  Health‐related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS).

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

TLDR
Post‐infectious irritable bowel syndrome is a common clinical phenomenon of uncertain aetiology that requires further investigation to determine its cause.

The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review

TLDR
Bifidobacterium infantis 35624 showed significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies; there is inadequate data to comment on the efficacy of other probiotics.

Role of gut microflora and probiotic effects in the irritable bowel syndrome.

TLDR
The increased colonisation by Bifi-dobacterium longum W11, after the cyclic administration of rifaximin, which eradicates the bacterial overgrowth of the small intestine, may reduce symptoms, especially those related to bowel habit and stool frequency in patients with IBS.